- Home
- AMAL vs ERAS Comparison
AMAL vs ERAS Comparison
Compare AMAL & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AMAL | ERAS |
|---|---|---|
| Founded | 1923 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 958.9M | 1.0B |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AMAL | ERAS |
|---|---|---|
| Price | $33.88 | $6.29 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $33.50 | $3.88 |
| AVG Volume (30 Days) | 197.5K | ★ 5.9M |
| Earning Date | 01-22-2026 | 11-12-2025 |
| Dividend Yield | ★ 1.67% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.32 | N/A |
| Revenue | ★ $305,836,000.00 | N/A |
| Revenue This Year | $10.09 | N/A |
| Revenue Next Year | $8.37 | N/A |
| P/E Ratio | $10.11 | ★ N/A |
| Revenue Growth | ★ 0.56 | N/A |
| 52 Week Low | $25.03 | $1.01 |
| 52 Week High | $37.26 | $6.85 |
Technical Indicators
Market Signals| Indicator | AMAL | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 64.93 | 78.83 |
| Support Level | $32.86 | $3.36 |
| Resistance Level | $34.43 | $6.49 |
| Average True Range (ATR) | 0.78 | 0.67 |
| MACD | -0.03 | 0.30 |
| Stochastic Oscillator | 80.18 | 83.76 |
Price Performance
Historical ComparisonAbout AMAL Amalgamated Financial Corp. (DE)
Amalgamated Financial Corp is a bank holding company. It is a full-service commercial bank and a chartered trust company. It provides commercial banking and trust services nationally and offers various products and services to commercial and retail customers. It offers a complete suite of commercial and retail banking, investment management and trust and custody services.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.